Therapeutic Product Immunogenicity Community

 View Only
  • 1.  in vitro immunogenicity assays

    Posted 11-25-2024 05:01

    Hello,

    We are exploring in vitro immunogenicity assays for ranking and de-risking human-derived monoclonal antibody candidates. Has anyone had any relevant experience with such assays offered by ProImmune? If so, we would appreciate any feedback. If you have recommendations for other providers, please do not hesitate.

    Thank you so much for your feedback.



    ------------------------------
    Cedric Cortijo
    Head of Bioanalytics
    Neurimmune AG
    Schlieren
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: in vitro immunogenicity assays

    Community Leadership
    Posted 12-09-2024 14:20

    Hi Cedric,

    There looks to be a number of presentations on different approaches for in vitro and in vivo assessment of immunogenicity potential at the EIP Symposium in February 2025: EIP | 2025 Lisbon

    Hopefully other can share their thoughts here (I think your original post landed around the Thanksgiving break...)

    Regards,

    Rob



    ------------------------------
    Robert Nelson
    Scientific Officer, Senior Director
    BioAgilytix Europe GmbH
    Hamburg Germany
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer or other entities to which I am affiliated.
    ------------------------------



  • 3.  RE: in vitro immunogenicity assays

    Posted 12-10-2024 14:46

    We published recently on in vitro assay for man immunogenicity. Please see this link if you are interested

    A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics - Communications Medicine

    Nature remove preview
    A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics - Communications Medicine
    Jarvi and Balu-Iyer evaluate an immunogenicity screening toolbox in which in vitro assays capture the migratory potential of dendritic cells. Expression of the chemokine receptor CXCR4 on dendritic cells and their migration toward chemokines CCL21 and CXCL12 in the presence of therapeutic protein correlates with their clinical immunogenicity.



    ------------------------------
    Sathy Balu-Iyer Ph.D., FAAPS
    Professor and Associate Dean for Research
    SUNY - University At Buffalo
    Buffalo NY
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 4.  RE: in vitro immunogenicity assays

    Posted 12-16-2024 07:23

    Thank you Robert and Sathy for your precious feedback.



    ------------------------------
    Cedric Cortijo
    Head of Bioanalytics
    Neurimmune AG
    Schlieren
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------